<?xml version="1.0" encoding="UTF-8"?>
<akn:akomaNtoso xmlns:akn="http://docs.oasis-open.org/legaldocml/ns/akn/3.0">
  <akn:act name="dc-code">
    <akn:meta>
      <akn:identification source="#cosilico">
        <akn:FRBRWork>
          <akn:FRBRuri value="/akn/us-dc/code/7-1305.06b"/>
          <akn:FRBRdate date="2025-12-31" name="retrieval"/>
          <akn:FRBRauthor href="#dc-council"/>
          <akn:FRBRcountry value="us-dc"/>
        </akn:FRBRWork>
        <akn:FRBRExpression>
          <akn:FRBRuri value="/akn/us-dc/code/7-1305.06b/eng@2025"/>
          <akn:FRBRdate date="2025-12-31"/>
          <akn:FRBRauthor href="#cosilico"/>
          <akn:FRBRlanguage language="en"/>
        </akn:FRBRExpression>
      </akn:identification>
    </akn:meta>
    <akn:body>
      <akn:section eId="sec_7_1305_06b">
        <akn:num>7-1305.06b</akn:num>
        <akn:heading>Review panel for administration of psychotropic medications.</akn:heading>
<akn:subsection eId="subsec_7-1305_06b_a">
      <akn:num>(a)</akn:num>
      <akn:content><akn:p>The DDS Administrator shall establish an independent panel to review all proposals to administer psychotropic medications to individuals made pursuant to § 7-1305.06a(c)(2) and in accordance with the administrative procedures established by DDS in accordance with subchapter I of Chapter 5 of Title 2 [§ 2-501 et seq.]. The administrative procedures established by DDS shall be consistent with the requirements of this section.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06b_b">
      <akn:num>(b)</akn:num>
      <akn:content><akn:p>The panel shall be comprised of 3 members. The members of the panel and their employers shall be immune from suit for any claim arising from any good faith act or omission under this section. The members of the panel shall not be affiliated with the individual, the provider, or the physician seeking to administer the medication, but shall include:</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06b_c">
      <akn:num>(c)</akn:num>
      <akn:content><akn:p>The administrative procedure established by DDS for the panel shall include, at a minimum:</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06b_d">
      <akn:num>(d)</akn:num>
      <akn:content><akn:p>If the individual requests a review by the DDS Human Rights Advisory Committee or its successor entity before the decision of the panel has been implemented, the decision shall not be implemented until after the DDS Human Rights Advisory Committee or its successor entity responds to the requested review. The DDS Human Rights Advisory Committee or its successor entity shall conduct the review at its next meeting or no later than 30 days after the request, whichever is earlier, and shall issue a response promptly.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06b_e">
      <akn:num>(e)</akn:num>
      <akn:content><akn:p>The panel shall issue a written decision which may grant, refuse, or withdraw consent to the prescription of the proposed psychotropic medication. The panel shall seek to conform as closely as possible to a standard of substituted judgment or, if the individual’s wishes are unknown and remain unknown after reasonable efforts to discern them, make the decision on the basis of the individual’s best interests. If the panel grants consent, the consent shall be granted for a limited period of time and shall last no longer than 9 consecutive months.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06b_f">
      <akn:num>(f)</akn:num>
      <akn:content><akn:p>For individuals for whom the panel has provided consent, DDS shall offer the individual the opportunity to execute a durable power of attorney in accordance with § 21-2205 and shall continue to seek to identify one or more individuals listed in § 21-2210(a) who may be reasonably available, mentally capable, and willing to act.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06b_g">
      <akn:num>(g)</akn:num>
      <akn:content><akn:p>For individuals for whom the panel has provided consent for 3 or more consecutive months, and for whom there is a reasonable likelihood that no decision-maker will become available and that the individual will not achieve capacity during the next 6 months to make decisions regarding psychotropic medications on his or her own behalf, the District shall petition the Court for appointment of a guardian pursuant to Chapter 20 of Title 21. The District’s petition shall request the type of guardianship which is least restrictive to the incapacitated individual in duration and scope, taking into account the incapacitated individual’s current mental and adaptive limitations or other conditions warranting the procedure. This subsection does not preclude any other party from petitioning the Court for appointment of a guardian.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06b_h">
      <akn:num>(h)</akn:num>
      <akn:content><akn:p>Refusal to consent to psychotropic medications shall not be used as evidence of an individual’s incapacity.</akn:p></akn:content>
    </akn:subsection><akn:subsection eId="subsec_7-1305_06b_i">
      <akn:num>(i)</akn:num>
      <akn:content><akn:p>Refusal to consent to services on the basis of a valid religious objection shall not be overridden absent a specific court order requiring the provision of services.</akn:p></akn:content>
    </akn:subsection>
      </akn:section>
    </akn:body>
  </akn:act>
</akn:akomaNtoso>
